The in-cell CSH change measurement technology by the cell therapy company Cell2in is simple and quantitative in real-time, and is receiving attention from the industry for it. AVING News interviewed Kang Heun-su, the CEO of Cell2in, which participated in the MIK HOT SPOT (Made in Korea Online Exhibition) KTVF.
Please introduce your company briefly.
Cell2in is a leader in the field of cell therapy. It was established in 2016 by outstanding researchers in Korea and abroad with the goal of becoming a global biopharmaceutical research institute, and focused on improving cell performance, we introduced innovative platform technology for quality control, evaluation, and application of cells. We have independently developed FreSHtracer™, an innovative platform technology for measuring the quality of living cells, the unmet need of cell therapy products.
Based on this, we have established strategic partnerships across the entire cell therapy industry to lead multilaterally active cooperation projects by cooperation with global bio companies. By applying this exclusive cell quality management technology industrially, we are developing disease-specific cell therapy, cell-specific culture media, animal disease therapy, cell-derived exosomes, and cell quality management system equipment.
Please describe the main technology.
It is a technology that evaluates the quality of cells by quantitatively measuring changes in glutathione (GSH) in living cells in real time. The method of measuring the amount of GSH in living cells can be easily, quickly and quantitatively measured in real time by adding our unique substance, FreSHtracerTM (Fluorescent real-time thiol tracer) fluorescent probe to the cell culture solution. The method for measuring the amount of change in GSH in cells is a technology that can efficiently evaluate the quality of living cells with an innovative test method that did not exist before. The research paper on our exclusive platform technology has been published in relevant journals and it patented as a source technology. To date, there are no other products, domestic or foreign, that have commercialized the technology to measure the change in the concentration of GSH in living cells in real time.
What are your plans for the future?
We are planning to commercialize the stem cell therapy business for pet diseases to well-known animal hospitals in Korea and worldwide, and also enter the pharmaceutical market with the dog disease cell therapy drug by receiving approval for disease-specific animal drug. Also, we are planning to conduct clinical trials of cell therapy products for rare refractory diseases through clinical research by researchers, and to conduct IND filing and clinical trials for refractory asthma (MSIT) and degenerative arthritis (MOHW) stem cell treatments, which are government-funded projects. In addition, we are planning to build a foundation for manufacturing technology for customized cell culture media (MSS), which is a project to support government research funds, and promote our technology to the US FDA as a guideline for measuring cell quality. We are also going to establish a collaborative research system with famous bio companies under clinical trials and cell therapy research abroad.
Direction sought by the company
Cell therapy is suggested as a new paradigm as an effective therapy for rare refractory diseases and refractory solid cancer. To verify the stability and efficacy of cell therapeutics using these cells, cell quality control is essential during manufacturing and storage. Accordingly, we have an exclusively-developed innovative cell quality evaluation platform technology, and we will use it to solve problems related to the quality of various cell therapy products (improving clinical therapeutic efficacy, manufacturing process, and quality control of cell therapy products).
Any last words you would like to say?
Our technology can be used for bioequivalence of cells and evaluation of quality of products in R&D or manufacturing process of cell therapy products. We are hoping for this technology to be used in institutions that develop and manufacture various bio researches in Korea and abroad to take the advantages of cell therapy products and gain cost competitiveness.
Korea Techno-Venture Foundation (KTVF), which supported companies participating in the MIK HOT SPOT (Made in Korea Online Exhibition), is a non-profit foundation funded by the Korea Institute of Science and Technology (KIST) to promote new technology startups and support global advancement. Since its establishment in 2001, it has established a close cooperation network with research institutes, universities and related institutions, as well as overseas organizations in Japan and the Eurasia region, and have promoted step-by-step customized support projects that connects “startup – fostering – commercialization – global marketing” to create the entrepreneurship ecosystem. KTVF said, “As an accelerator that supports global technology commercialization through discovering, fostering, and investing in tech-startups with high growth potential, we intend to contribute to the success and job creation of small and medium-sized venture companies.”
The global news network AVING News has begun holding the MIK Hot Spot (Made in Korea Online Exhibition) to help small and medium-sized companies enter the market and attract investment 365 days a year’ AVING News has been running online exhibitions since 2005 and had 975 online exhibitions so far. Its YouTube online exhibition has placed itself as Korea’s largest online exhibition hall that opens with 19,000 videos (booths) with more than 800,000 visits per month which means more than 10 million visits per year.
The MIK HOT SPOT online exhibition is scheduled to be held regularly according to the field, target market, and participating institutions, and it will be presented as a new type of online business by transforming the know-hows and values of the participating companies according to the trend. Companies that want to participate can apply and apply through the marketing support projects from supporting institutions in the local governments. Refer to the institutions for more information.tecaving2020-08-12T06:05:30+00:00